Parasympatholytic drugs legal definition of parasympatholytic drugs
What is parasympatholytic drugs? Meaning of parasympatholytic drugs as a legal term. What does parasympatholytic drugs mean in ... Definition of parasympatholytic drugs in the Legal Dictionary - by Free online English dictionary and encyclopedia. ... redirected from parasympatholytic drugs). Also found in: Dictionary, Thesaurus, Medical, Encyclopedia. drug. noun alterant, ... Parasympatholytic drugs legal definition of parasympatholytic drugs https://legal-dictionary.thefreedictionary.com/ ...http://legal-dictionary.thefreedictionary.com/parasympatholytic+drugs
Parasympatholytic - Wikipedia
"Dorlands Medical Dictionary:parasympatholytic". Overview at salisbury.edu Parasympatholytics at the US National Library of ... Most drugs with parasympatholytic properties are anticholinergics. "Parasympatholytic" and sympathomimetic agents have similar ... A parasympatholytic agent is a substance or activity that reduces the activity of the parasympathetic nervous system. (The ... Parasympatholytic drugs are sometimes used to treat slow heart rhythms (bradycardias or bradydysrhythmias) caused by myocardial ...https://en.wikipedia.org/wiki/Parasympatholytic
Lytispasm - Anticholinergics, Parasympatholytics
Anisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder. In general, smaller doses of anisotropine methylbromide inhibit salivary and bronchial secretions, sweating, and accommodation; cause dilatation of the pupil; and increase the heart rate. Larger doses are required to decrease motility of the gastrointestinal and urinary tracts and to inhibit gastric acid secretion ...http://pharmacycode.com/Lytispasm.html
Biperidine Hydrochloride - Antiparkinson Agents, Antidyskinetics, Muscarinic Antagonists, Parasympatholytics...
Biperiden is a weak peripheral anticholinergic agent. It has, therefore, some antisecretory, antispasmodic and mydriatic effects. In addition, biperiden possesses nicotinolytic activity. The parenteral form of biperiden is an effective and reliable agent for the treatment of acute episodes of extrapyramidal disturbances sometimes seen during treatment with neuroleptic agents. Akathisia, akinesia, dyskinetic tremors, rigor, oculogyric crisis, spasmodic torticollis, and profuse sweating are markedly reduced or eliminated. With parenteral biperiden, these drug-induced disturbances are rapidly brought under control ...http://pharmacycode.com/Biperidine_Hydrochloride.html
Parasympatholytic - Parosteosis, Parostosis | Taber's® Cyclopedic Medical Dictionary, 23e | F.A. Davis PT Collection | McGraw...
"Parasympatholytic - Parosteosis, Parostosis." Taber's® Cyclopedic Medical Dictionary, 23e Venes D. Venes D Ed. Donald Venes. ... Parasympatholytic - Parosteosis, Parostosis. In: Venes D. Venes D Ed. Donald Venes.eds. Taber's® Cyclopedic Medical Dictionary ...http://fadavispt.mhmedical.com/content.aspx?bookid=2132§ionid=174142260
Isopto-atropine - Adjuvants, Anesthesia, Anti-Arrhythmia Agents, Bronchodilator Agents, Muscarinic...
Atropine is commonly classified as an anticholinergic or antiparasympathetic (parasympatholytic) drug. More precisely, however ...http://pharmacycode.com/Isopto-atropine.html
Tropic acid, ester with tropine - Adjuvants, Anesthesia, Anti-Arrhythmia Agents, Bronchodilator Agents, ...
Atropine is commonly classified as an anticholinergic or antiparasympathetic (parasympatholytic) drug. More precisely, however ...http://pharmacycode.com/Tropic_acid%2C_ester_with_tropine.html
Cardiac Flashcards by Kimberlee Ward | Brainscape
Study Cardiac flashcards from Kimberlee Wardhttps://www.brainscape.com/flashcards/cardiac-5055562/packs/7485724
Patent US6517869 - Positively charged poly(alpha-(omega-aminoalkyl)lycolic acid) for the ... - Google Patents
... parasympatholytics; psychostimulants; sedatives; and tranquilizers. By the method of the present invention, both ionized and ...http://www.google.com/patents/US6517869
Patent US5122383 - Sorbitan esters as skin permeation enhancers - Google Patents
... parasympatholytics; psychostimulants; sedatives; and tranquilizers. For purposes of the aforementioned definition, "drugs" as ...http://www.google.com/patents/US5122383?dq=oakley+D523,461
Patent US20040254635 - Expandable medical device for delivery of beneficial agent - Google Patents
... parasympatholytics; parasympathomimetrics; prostaglandins; proteins; peptides; psychostimulants; sedatives; and tranquilizers. ...http://www.google.co.uk/patents/US20040254635
Patent US6967234 - Alkyd-lactone copolymers for medical applications - Google Patents
... parasympatholytics, psychostimulants, sedatives, tranquilizers, naturally derived or genetically engineered proteins, growth ... parasympatholytics; psychostimulants; sedatives; tranquilizers; naturally derived or genetically engineered proteins, growth ...http://www.google.com/patents/US6967234?dq=5,664,133
Patent US5883135 - Composition, device, and method for enhanced electrotransport agent delivery - Google Patents
... parasympatholytics; parasympathomimetrics; prostaglandins; proteins; peptides; psychostimulants; sedatives and tranquilizers. ...http://www.google.com/patents/US5883135?dq=5,666,293
Patent US6908448 - Substance delivery device - Google Patents
... parasympatholytics; psychostimulants; sedatives; and tranquilizers. By the method of the present invention, ionized and ...http://www.google.com/patents/US6908448?dq=7,054,745
Neural Responses and Dysphoria: Modulation by a Pharmacological Probe - Full Text View - ClinicalTrials.gov
Parasympatholytics. Autonomic Agents. Peripheral Nervous System Agents. Muscarinic Antagonists. Cholinergic Antagonists. ...https://clinicaltrials.gov/show/NCT01101685
Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain - Full Text View - ClinicalTrials.gov
Parasympatholytics. Autonomic Agents. Peripheral Nervous System Agents. Muscarinic Antagonists. Cholinergic Antagonists. ...https://clinicaltrials.gov/ct2/show/NCT00227292?recr=Open&cond=%22Back+Pain%22&rank=16
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg...
Parasympatholytics. Cholinergic Antagonists. Cholinergic Agents. Neurotransmitter Agents. Molecular Mechanisms of ...https://clinicaltrials.gov/ct2/show/NCT01627327
Validation of Surrogate Measures in Irritable Bowel Syndrome (IBS) - Full Text View - ClinicalTrials.gov
Parasympatholytics. Autonomic Agents. Peripheral Nervous System Agents. Muscarinic Antagonists. Cholinergic Antagonists. ...https://clinicaltrials.gov/ct2/show/NCT00693732
Ocular Response Analyzer Assessment of Intraocular Pressure and Corneal Biomechanical Properties in Myopic and Anisometropic...
Parasympatholytics. Muscarinic Antagonists. Cholinergic Antagonists. Cholinergic Agents. Neurotransmitter Agents. Molecular ...https://clinicaltrials.gov/ct2/show/NCT00658502?recr=Open&cond=%22Refractive+Errors%22&rank=18
Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity - Full Text View - ClinicalTrials.gov
Parasympatholytics. Cholinergic Antagonists. Cholinergic Agents. Neurotransmitter Agents. Molecular Mechanisms of ...https://clinicaltrials.gov/ct2/show/NCT00999908
The Analgesic Activity of a Topical Formulation in Patients With Osteoarthritis of the Hands - Full Text View - ClinicalTrials...
Osteoarthritis (OA) affects over 30 million people in the United States and represents our nation's leading cause of disability. Data for the years between 1996-2005, indicate that OA raised overall health care costs by $185.5 billion annually. Largely as a consequence of this disease, the number of patients undergoing joint replacement surgery will quadruple over the next 17 years. Importantly, several recent studies have demonstrated that OA is an independent risk factor for cardiovascular disease . Presently investigators have no medications that alter the natural history of OA. Weight control, exercise and some physical therapy measures are the only interventions short of total joint replacement that alter the course of this disease. To make matters worse, investigators have experienced only setbacks in use of medications aimed at symptom control. Recognition of toxicities of non-steroidal anti-inflammatory drugs (NSAIDs) and narcotic-based analgesics has narrowed the presently available ...https://clinicaltrials.gov/ct2/show?term=topical+gels+AND+transdermal&rank=5
Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck...
In-hospital Cardiac Arrest - Dynamics and State Transitions - Full Text View - ClinicalTrials.gov
In-hospital cardiac arrest carries a grave prognosis, with survival to discharge in the range of 15-20%. Key factors determining outcome include the presenting cardiac rhythm, aetiology, and early initiation of resuscitation. Some cardiac rhythms benefit from defibrillation (shockable rhythms). During resuscitation patients may switch between shockable and non-shockable rhythms, and may show signs of spontaneous circulation temporarily. Depending on rhythm and according to guidelines, patients receive direct current (DC) shocks (defibrillator) and/or i.v. adrenaline, atropine and amiodarone, which may affect state-transitions. We wish to make statistical analysis (time-series analysis, Markov modelling) of these state-transitions and variations in hemodynamic variables during resuscitation, related to CPR interventions and the cause of arrest. The cause of arrest will be determined based on chart records, interview with staff and autopsy if appropriate. One hypothesis is that differences in the ...https://clinicaltrials.gov/ct2/show/NCT00920244?recr=Open&cond=%22Death%2C+Sudden%2C+Cardiac%22&rank=7
Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting - Full Text View -...
Postoperative nausea and vomiting (PONV) is a serious problem complicating surgery. PONV has an overall incidence of 30% and a 70% incidence in high-risk patients. PONV yields unplanned hospital admission, pulmonary aspiration, esophageal rupture, electrolyte abnormalities, dehydration, and delayed discharge from the postanesthesia care unit (PACU). Additional use of resources costs the health care industry hundreds of millions of dollars annually. Patient satisfaction is greatly improved when PONV is prevented.4 PONV etiology is multifactorial and the treatment is multimodal ...https://clinicaltrials.gov/ct2/show/NCT00659737
Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation - Full Text...
Parasympatholytics. Muscarinic Antagonists. Cholinergic Antagonists. Cholinergic Agents. Neurotransmitter Agents. Molecular ...https://clinicaltrials.gov/ct2/show/NCT01042600